Kisho

Nacuity Pharmaceuticals, Inc. — Rare Disease Pipeline | Kisho

Nacuity Pharmaceuticals, Inc.

Other

Orphan Designations

0 approved, 3 designated

FDA Approvals

Active Trials

Rare Diseases

across 11 areas

News (30d)

Quiet

Nacuity Pharmaceuticals, Inc. is a company with 3 orphan drug designations across 5 rare diseases. 1 active policy bill affects their portfolio.

Competitive Landscape

Diversified Portfolio

Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.

Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA

Approved: 0

In Trials: 0

Designated Only: 5

5 total diseases

Disease	Drug(s)	Stage
cystinosis	N-acetylcysteine amide	Des.TrialAppr.
malignant carotid body paraganglioma	N-acetylcysteine amide	Des.TrialAppr.
post-treatment Lyme disease syndrome	N-acetylcysteine amide	Des.TrialAppr.
retinitis pigmentosa	N-acetyl cysteine amide	Des.TrialAppr.
treatment-refractory schizophrenia	N-acetylcysteine amide	Des.TrialAppr.